It is still unclear whether any specific treatment strategy for FLT3-mutated AML can reduce the risk of CNS relapse after alloSCT; while previous studies have demonstrated the intracranial activity of both sorafenib and gilteritinib, the rates of CNS recurrence post-alloSCT have not been reported in either of these trials.27,28. The gene discussed is FLT3; the disease is acute myeloid leukemia.